Pfizer (PFE.US) Tukysa receives U.S. approval for first-line breast cancer treatment
智通财经2026/10/08 02:41According to Zhitong Finance APP, Pfizer (PFE.US) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved its tyrosine kinase inhibitor Tukysa (tucatinib) as part of a combination therapy for first-line maintenance treatment of a certain type of breast cancer.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
GBP/JPY hits 209.00, up 0.07% intraday
GBP/JPY has just reached the 209.00 level, latest quoted at 209.00, up 0.07% on the day.
INE crude oil main contract breaks through 740 yuan/barrel, rising 6.35% intraday.
The main contract of China's INE crude oil futures has just broken through the 740.0 yuan/barrel mark, now quoted at 740.3 yuan/barrel, up 6.35% intraday.
Wolfspeed (WOLF.US), a silicon carbide chip manufacturer, receives a loan of up to 1.5 billions USD from the U.S. Department of Defense and surges after hours.
The US Department of Defense has committed to providing Wolfspeed, a silicon carbide chip manufacturer, with a conditional loan of up to $1.5 billions to support the company's development of materials it describes as critical to national security.
Wolfspeed (WOLF.US), a silicon carbide chip manufacturer, surges after hours following approval for a maximum $1.5 billion loan from the U.S. Department of Defense.
According to Zhihui Finance APP, the US Department of Defense has pledged to provide a conditional loan of up to $1.5 billion to silicon carbide chip manufacturer Wolfspeed (WOLF.US) to support the development of materials the company claims are critical to national security. Boosted by this news, Wolfspeed's shares surged nearly 19% in after-hours US trading on Wednesday.
Crypto prices
More
